Well Done LLC’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.2M | Buy |
48,290
+42
| +0.1% | +$9.04K | 1.63% | 13 |
|
|
2026
Q1 | $10.5M | Sell |
48,248
-928
| -2% | -$206K | 1.54% | 15 |
|
|
2025
Q4 | $11.2M | Sell |
49,176
-74
| -0.2% | -$16.9K | 1.68% | 14 |
|
|
2025
Q3 | $11.4M | Sell |
49,250
-375
| -0.8% | -$76.4K | 1.94% | 11 |
|
|
2025
Q2 | $9.21M | Sell |
49,625
-58
| -0.1% | -$10.8K | 1.73% | 10 |
|
|
2025
Q1 | $8.83M | Buy |
49,683
+78
| +0.2% | +$15.2K | 1.6% | 11 |
|
|
2024
Q4 | $9.8M | Hold |
49,605
| – | – | 1.79% | 11 |
|
|
2024
Q3 | $9.8M | Buy |
49,605
+69
| +0.1% | +$12.9K | 1.79% | 11 |
|
|
2024
Q2 | $8.5M | Sell |
49,536
-36
| -0.1% | -$5.96K | 1.77% | 11 |
|
|
2024
Q1 | $9.03M | Sell |
49,572
-566
| -1% | -$97.5K | 1.78% | 11 |
|
|
2023
Q4 | $7.77M | Buy |
50,138
+10
| +0% | +$1.46K | 1.52% | 13 |
|
|
2023
Q3 | $7.47M | Buy |
50,128
+50
| +0.1% | +$7.34K | 1.66% | 11 |
|
|
2023
Q2 | $6.75M | Sell |
50,078
-7,773
| -13% | -$1.14M | 1.43% | 13 |
|
|
2023
Q1 | $9.22M | Sell |
57,851
-1
| -0% | -$153 | 1.99% | 11 |
|
|
2022
Q4 | $9.35M | Sell |
57,852
-31
| -0.1% | -$4.75K | 2.01% | 10 |
|
|
2022
Q3 | $7.77M | Buy |
57,883
+100
| +0.2% | +$14.3K | 1.9% | 12 |
|
|
2022
Q2 | $8.85M | Sell |
57,783
-392
| -0.7% | -$59.9K | 1.95% | 12 |
|
|
2022
Q1 | $9.43M | Sell |
58,175
-525
| -0.9% | -$76.3K | 1.89% | 11 |
|
|
2021
Q4 | $7.95M | Buy |
58,700
+171
| +0.3% | +$20.2K | 1.61% | 11 |
|
|
2021
Q3 | $6.31M | Sell |
58,529
-301
| -0.5% | -$34.4K | 1.41% | 12 |
|
|
2021
Q2 | $6.63M | Sell |
58,830
-125
| -0.2% | -$14.1K | 1.46% | 13 |
|
|
2021
Q1 | $6.38M | Sell |
58,955
-502
| -0.8% | -$53.7K | 1.46% | 14 |
|
|
2020
Q4 | $6.37M | Buy |
59,457
+7
| +0% | +$673 | 1.58% | 14 |
|
|
2020
Q3 | $5.21M | Buy |
59,450
+57
| +0.1% | +$5.37K | 1.47% | 15 |
|
|
2020
Q2 | $5.83M | Sell |
59,393
-1,191
| -2% | -$105K | 1.6% | 15 |
|
|
2020
Q1 | $4.62M | Sell |
60,584
-1,463
| -2% | -$125K | 1.4% | 15 |
|
|
2019
Q4 | $5.49M | Buy |
62,047
+46
| +0.1% | +$3.82K | 1.27% | 20 |
|
|
2019
Q3 | $4.7M | Buy |
62,001
+9
| +0% | +$617 | 1.15% | 24 |
|
|
2019
Q2 | $4.51M | Buy |
61,992
+8
| +0% | +$629 | 1.05% | 26 |
|
|
2019
Q1 | $5M | Sell |
61,984
-19
| -0% | -$1.55K | 1.23% | 20 |
|
|
2018
Q4 | $5.72M | Sell |
62,003
-562
| -0.9% | -$49.4K | 1.6% | 12 |
|
|
2018
Q3 | $5.92M | Buy |
62,565
+86
| +0.1% | +$8.15K | 1.67% | 13 |
|
|
2018
Q2 | $5.79M | Buy |
62,479
+285
| +0.5% | +$27.8K | 1.73% | 13 |
|
|
2018
Q1 | $5.89M | Sell |
62,194
-100
| -0.2% | -$11K | 1.83% | 11 |
|
|
2017
Q4 | $6.03M | Sell |
62,294
-1,514
| -2% | -$143K | 1.97% | 12 |
|
|
2017
Q3 | $5.67M | Sell |
63,808
-50
| -0.1% | -$3.81K | 1.74% | 16 |
|
|
2017
Q2 | $4.63M | Hold |
63,858
| – | – | 1.62% | 17 |
|
|
2017
Q1 | $4.16M | Sell |
63,858
-337
| -0.5% | -$21.2K | 1.48% | 19 |
|
|
2016
Q4 | $4.02M | Buy |
64,195
+37
| +0.1% | +$2.26K | 1.52% | 21 |
|
|
2016
Q3 | $4.05K | Sell |
64,158
-790
| -1% | -$51.1K | 1.46% | 20 |
|
|
2016
Q2 | $4.02M | Hold |
64,948
| – | – | 1.46% | 17 |
|
|
2016
Q1 | $3.71M | Hold |
64,948
| – | – | 1.35% | 18 |
|
|
2015
Q4 | $3.85M | Buy |
+64,948
| New | +$3.74M | 1.36% | 17 |
|
Other funds holding ABBV
Well Done LLC's ABBV Position: Q2 2026 in Review
Well Done LLC increased its AbbVie (ABBV) stake by 0.09% in Q2 2026, buying an estimated $9.04K and bringing the position to 48,290 shares worth $12.2M. The position accounts for 1.63% of the portfolio, ranked #13.
Well Done LLC first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Well Done LLC held 48,290 shares of AbbVie worth $12.2M as of Q2 2026.
- Well Done LLC bought 42 AbbVie shares in Q2 2026, an estimated $9.04K.
- AbbVie made up 1.63% of Well Done LLC's portfolio in Q2 2026, its #13 holding.
- Well Done LLC first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Well Done LLC's 13F filing for Q2 2026, filed 24 Jul 2026.